Barclays Upgrades Ionis Pharmaceuticals (IONS) Stock to 'Overweight'

Barclays upgraded Ionis Pharmaceuticals (IONS) stock to “Overweight” from “Equal Weight” with a price target of $57, ahead of Tryngolza Phase 3 data in severe hypertriglyceridemia. The firm expects high trial success rates. Ionis also reported positive Phase 1 results for salanersen in treating spinal muscular atrophy, leading to a 10% revenue increase in Q1 2025.

While acknowledging IONS’ potential, some AI stocks offer greater upside. For an undervalued AI stock with tariff benefits, check out a free report. Visit Insider Monkey for more investment insights.

Read more at Yahoo Finance: Barclays Upgrades Ionis Pharmaceuticals (IONS) Stock, Raises PT